Faster global financial news!
Bristol-Myers Squibb
-
Yahoo Finance Analysis: Bristol Myers Squibb (BMY) is a solid buy among healthcare stocks, with a forward yield nearing 4%, as patent cliff fears are deemed overblown.
The analysis notes that despite a major patent cliff, with Eliquis and Opdivo losing U.S. patent exclusivity in 2028, Bristol Myers Squibb's stock appears cheap at under 10 times forward earnings. Ana
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Morgan Stanley maintained an "Underweight" rating on Bristol Myers Squibb (BMY) with a price target of $40, significantly below the current share price, due to patent expiration risks and delays in new drug development.
Despite Bristol Myers Squibb's strong second-quarter results and an upward revision to its full-year 2026 revenue forecast, Morgan Stanley reiterated its "Underweight" rating and a price target of $40
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
-
Yahoo Finance Analysis: Bristol Myers Squibb (BMY) is a solid buy among healthcare stocks, with a forward yield nearing 4%, as patent cliff fears are deemed overblown.
The analysis notes that despite a major patent cliff, with Eliquis and Opdivo losing U.S. patent exclusivity in 2028, Bristol Myers Squibb's stock appears cheap at under 10 times forward earnings. Ana
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Morgan Stanley maintained an "Underweight" rating on Bristol Myers Squibb (BMY) with a price target of $40, significantly below the current share price, due to patent expiration risks and delays in new drug development.
Despite Bristol Myers Squibb's strong second-quarter results and an upward revision to its full-year 2026 revenue forecast, Morgan Stanley reiterated its "Underweight" rating and a price target of $40
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
- No data
Bristol-Myers Squibb
24H Trending
-
1
SoftBank Group's record $6.45 billion retail bond sale on Thursday will boost its share of Japan's corporate retail bond market to nearly 50%
-
2
Ethereum founder Vitalik Buterin tweeted a comment on the ancient Chinese philosopher Mozi, calling his thought "proto d/acc."
-
3
Lookonchain monitoring shows Garrett Jin, the largest on-chain ZEC short, is now down over $26M, holding a $51.5M short position with a liquidation price of $2,631.53.
-
4
Ethereum founder Vitalik Buterin: Qwen 3.8 Flash model's performance is impressive, local models are expected to handle a large number of tasks
-
5
New Zealand's sovereign wealth fund has achieved a 14.2% annual return, ranking first globally, but its CEO warns that high returns in US equities are unsustainable.
-
6
Japanese chip material makers Resonac Holdings and Nitto Denko will invest in a US fund to seek cooperation in AI hardware.
-
7
Posco International acquires US shale gas asset for $550 million
-
8
Samsung's Rainbow Robotics halts US robot shipments due to new American restrictions, plans to seek approval and US production
-
9
AI boom tightens MLCC supply, giving Samsung Electro-Mechanics pricing power as it begins raising prices
-
10
Federal Judge Orders X and SpaceXAI to Disclose Secret Apple Agreement by Thursday in Musk's Antitrust Case
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
